Teva Pharmaceutical Industries (FRA:TEV) Moat Score: 5/10 (As of Jul. 12, 2026)


FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
58 GF Score
Price €28.50
GF Value €17.67
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Moat Score?

Teva Pharmaceutical Industries FRA:TEV 58 Moat Score is 5 as of Jul. 12, 2026. GuruFocus rates FRA:TEV with a GF Score™ of 58/100 and a GF Value™ of €17.67 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 94.67% on this metric.

Teva Pharmaceutical Industries has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Teva Pharmaceutical Industries has Narrow Moat: Teva has a solid narrow moat due to its extensive portfolio of generic drugs and economies of scale. However, intense competition and limited pricing power in the pharmaceutical industry prevent it from achieving a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Teva Pharmaceutical Industries might have Narrow Moat - Solid narrow moat.

Teva Pharmaceutical Industries  (FRA:TEV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Teva Pharmaceutical Industries Moat Score Related Terms

FRA:TEV vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Moat Score distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Moat Score falls into.


FRA:TEV
58GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Teva Pharmaceutical Industries (FRA:TEV) has a Moat Score of 5 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Teva Pharmaceutical Industries' Moat Score too high?
Teva Pharmaceutical Industries' current Moat Score is 5. Based on the distribution chart, Teva Pharmaceutical Industries ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Teva Pharmaceutical Industries has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #55 out of 1031 companies for Moat Score. This places Teva Pharmaceutical Industries in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Teva Pharmaceutical Industries's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.67, compared to a current price of €28.50 — trading 61.3% above its estimated fair value. The current Moat Score is 5. Teva Pharmaceutical Industries' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Moat Score is 5 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €28.50 is trading 61.3% above its estimated GF Value™ of €17.67. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • Moat Score: 5
  • GF Value™: €17.67 vs. price of €28.50 (61.3% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score

Get the complete analysis for FRA:TEV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.50
Price
€17.67
GF Value